9/8/2022 | CVLM | Intercept closes $9.3 million private convertible note exchange
|
8/19/2022 | CV | Market Commentary: Convertibles secondary ‘dead as a doornail’; Bill.com spikes; Intercept exchanges
|
8/19/2022 | CVLM | Intercept Pharmaceuticals to buy $327.9 million of 3.5% convertibles
|
8/19/2022 | CV | Market Commentary: Morning Commentary: Convertibles secondary ‘dead as a doornail’ in early trading
|
9/13/2021 | CVLM | Intercept Pharmaceuticals to buy $39.9 million of 3.25% convertibles
|
8/11/2021 | CV | Market Commentary: Fisker on tap; Cloudflare, Avalara convertibles struggle on debut; Intercept below par
|
8/11/2021 | CVLM | Intercept Pharmaceuticals privately swaps and issues new convertibles
|
8/11/2021 | CV | New Issue: Intercept Pharmaceuticals privately swaps and issues new convertibles
|
6/29/2020 | CV | Market Commentary: PG&E equity units active; AA improves; Intercept tanks; Chesapeake files for bankruptcy
|
12/2/2019 | CV | Market Commentary: Convertibles secondary slow; Intercept, Clovis bull run continues; Akamai notes active
|
11/25/2019 | CV | Market Commentary: Medicines convertibles in focus on buyout; Intercept expands; Liberty Media improves
|
7/10/2019 | CV | Market Commentary: Convertibles secondary firm; YY in focus; Chesapeake Energy active; Intercept comes in
|
6/26/2019 | SP | New Issue: CIBC sells $133,000 notes tied to 14 Raymond James Healthcare top picks
|
6/26/2019 | SP | New Issue: CIBC sells $253,000 notes tied to 14 Raymond James Healthcare top picks
|
6/17/2019 | CV | Market Commentary: Change Healthcare on tap; DISH Network expands; Array skyrockets outright on buyout
|
6/17/2019 | CV | Market Commentary: Morning Commentary: Secondary trading light; health care sector boosted by Array buyout
|
6/7/2019 | SP | CIBC plans Raymond James Healthcare Top Selections notes on 14 stocks
|
6/7/2019 | SP | CIBC eyes Raymond James Healthcare Top Selections notes on 14 stocks
|
5/30/2019 | SP | New Issue: CIBC sells $370,000 Raymond James Healthcare Top Selections notes on 15 stocks
|
5/30/2019 | SP | New Issue: CIBC sells $1.64 million Raymond James Healthcare Top Selections notes on 15 stocks
|
5/13/2019 | CV | Market Commentary: Tesla in focus, contracts; Weatherford trades down on bankruptcy; Western Digital lower
|
5/10/2019 | CV | Market Commentary: Intercept convertible notes hit the market, expand; Zillow expands; Booking active
|
5/10/2019 | CV | Market Commentary: Morning Commentary: Intercept convertible notes hit the market, expand; Zillow active
|
5/10/2019 | CV | New Issue: Intercept Pharmaceuticals prices $200 million seven-year convertibles at 2%, up 30%
|
5/9/2019 | CV | Market Commentary: Intercept Pharmaceuticals offering eyed; Infinera tanks on earnings; Avaya contracts
|
5/9/2019 | CV | Market Commentary: Morning Commentary: Intercept Pharmaceuticals offering eyed; Infinera tanks on earnings
|
5/8/2019 | CV | Market Commentary: Intercept on tap; Workday eyed; Fortive expands; j2 Global contracts; Microchip active
|
5/8/2019 | CV | Intercept Pharmaceuticals talks $200 million seven-year convertibles to yield 1.5%-2%, up 30%-35%
|
4/11/2019 | CV | Market Commentary: PAR Technology convertible notes expand; Intercept down outright, up on hedge; biotechs active
|
4/11/2019 | CV | Market Commentary: Morning Commentary: PAR Technology convertible expands; Intercept below par
|
2/20/2019 | CV | Market Commentary: Fortive’s convertibles hit market, expand on debut; Intercept contracts; Aceto eyed
|
2/19/2019 | CV | Market Commentary: Fortive offers $1.25 billion convertibles; Ovid on tap; Western Digital, Intercept eyed
|
10/31/2018 | SP | New Issue: BMO sells $292,000 notes on eight Raymond James biotechnology top picks
|
10/31/2018 | SP | New Issue: BMO sells $390,000 notes on eight Raymond James biotechnology top picks
|
10/11/2018 | SP | BMO plans notes due 2020 tied to Raymond James biotech top picks
|
10/11/2018 | SP | BMO to price notes due 2020 tied to Raymond James biotech top picks
|
10/8/2018 | SP | New Issue: BMO sells $1.23 million notes on eight Raymond James Biotechnology Sector top picks
|
10/8/2018 | SP | New Issue: BMO sells $1.02 million notes on eight Raymond James Biotechnology Sector top picks
|
8/15/2018 | CV | Market Commentary: Illumina on tap; market eyes New Mountain, FTI; Enphase Energy prices; Canopy jumps
|
8/6/2018 | CV | Market Commentary: Convertibles see tame start to week, Intercept, Dish expand; Extra Space, Palo Alto active
|
8/6/2018 | CV | Market Commentary: Morning Commentary: Convertibles see tame start to week, Intercept jumps
|
5/31/2018 | CV | Market Commentary: GDS hits the market; new issue volume to pick up next week; Red Hat active; Alder gains
|
10/6/2017 | CV | Market Commentary: Convertibles market quiet as shares slip from record highs on jobs data; Intercept active
|
10/6/2017 | CV | Market Commentary: Morning Commentary: Convertible primary, secondary quiet; Intercept active as shares drop again
|
9/26/2017 | CV | Market Commentary: Air Transport’s new convertibles break above par; IAC/InterActive on deck; Red Hat firm
|
9/22/2017 | CV | Market Commentary: Intercept Pharmaceuticals gaps down; Merrimack, Wayfair lower; new issuance light during week
|
9/22/2017 | CV | Market Commentary: Morning Commentary: Marriott Vacations remains in focus; Intercept slide continues
|
9/21/2017 | CV | Market Commentary: Marriott Vacations adds on swap; Intercept drops about 9 points outright after FDA warning
|
9/12/2017 | CV | Market Commentary: Wayfair’s new 0.375% convertibles trade up in heavy volume; Workday on tap; Teva firm
|
8/1/2017 | CV | Market Commentary: Innoviva’s ‘old’ convertibles active ahead of new issue pricing; Intercept remains weak
|
7/31/2017 | CV | Market Commentary: Intercept Pharmaceuticals topical on results, trial data; Hercules Capital unchanged
|
6/19/2017 | CV | Market Commentary: Clovis Oncology convertibles jump over 25 points on positive trial data; biotech follows
|
9/16/2016 | SP | New Issue: HSBC prices $3 million of AMPS linked to basket of 20 common stocks
|
9/8/2016 | SP | HSBC plans 15-month AMPS with cap linked to basket of 20 stocks
|
7/6/2016 | CV | Intercept greenshoe exercised, ups 3.25% convertibles to $460 million
|
7/5/2016 | PP | Market Commentary: Post-holiday convertible bond trading subdued; Intercept’s new issue lower; Akamai gains
|
7/5/2016 | CV | Market Commentary: Post-holiday convertible bond trading subdued; Intercept’s new issue lower; Akamai gains
|
7/5/2016 | CV | Market Commentary: Morning Commentary: Post-holiday convertible bond trading subdued; Intercept’s new issue quiet
|
7/1/2016 | PP | Market Commentary: Convertibles quiet ahead of holiday; Exelixis in line; Softbank/Alibaba mandatories better
|
7/1/2016 | CV | Market Commentary: Convertibles quiet ahead of holiday; Exelixis in line; Softbank/Alibaba mandatories better
|
7/1/2016 | CV | Market Commentary: Morning Commentary: Convertibles quiet ahead of holiday weekend; Exelixis trading in line
|
6/30/2016 | PP | Market Commentary: Convertibles mostly recover with shares; new Intercept convertible gains in active trade
|
6/30/2016 | CV | Market Commentary: Convertibles mostly recover with shares; new Intercept convertible gains in active trade
|
6/30/2016 | CV | Market Commentary: Morning Commentary: New Intercept convertible adds on swap in active trade as shares slip
|
6/30/2016 | CV | New Issue: Intercept Pharmaceuticals sells $400 million seven-year convertibles at 3.25%, up 32.5%
|
6/29/2016 | PP | Market Commentary: Tesaro surges after positive drug data; Tesla lower; Intercept Pharmaceuticals on tap
|
6/29/2016 | CV | Market Commentary: Tesaro surges after positive drug data; Tesla lower; Intercept Pharmaceuticals on tap
|
6/29/2016 | CV | Intercept Pharmaceuticals plans $400 million seven-year convertibles to yield 3%-3.5%, up 30%-35%
|
6/11/2015 | SP | New Issue: JPMorgan prices $3.26 million capped return enhanced notes on S&P 500
|
6/24/2013 | PP | Intercept greenshoe exercised for $65.67 million public sale of stock
|
6/19/2013 | PP | Intercept prices $57.11 million public sale of common stock at $33.01
|
6/17/2013 | PP | Intercept plans to price public offering of 1.73 million common shares
|
10/15/2012 | PP | Intercept greenshoe fully exercised for total IPO of $86.25 million
|
10/11/2012 | PP | Intercept prices $75 million initial public stock offering at $15.00
|
9/4/2012 | PP | Intercept Pharmaceuticals to price initial public sale of common stock
|
5/16/2006 | BT | Intercept Pharmaceuticals closes $41 million equity financing
|